De­nali broad­ens tech to in­fil­trate the blood-brain bar­ri­er with Siri­on deal

Keen­ly-watched neu­ro drug de­vel­op­er De­nali $DNLI is beef­ing up its ar­se­nal to smug­gle drugs across the brain-blood bar­ri­er. The San Fran­cis­co-based com­pa­ny joined forces with Siri­on Biotech to de­vel­op ade­no-as­so­ci­at­ed virus (AAV) vec­tors to en­able ther­a­peu­tics to cross the blood-brain bar­ri­er and tar­get dis­eases of the cen­tral ner­vous sys­tem, such as Alzheimer’s, Parkin­son’s and Lou Gehrig’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER